CAV3 as therapeutic target for mitochondrial dysfunction in diabetic cardiomyopathy
May 8, 2024
Researchers from Huazhong University of Science and Technology and collaborators published results from a study that aimed to assess the potential role of caveolin 3 (CAV3) in mitochondrial function during diabetic cardiomyopathy (DCM).